Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
British Journal of Cancer
|
February 5, 2009
Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group
I Ray-Coquard, B Weber, J Cretin, et al.
ESMO Open
|
April 12, 2025
Exposure-response relationship of niraparib in maintenance therapy for recurrent ovarian cancer: ancillary analysis of the French GINECO-NiQoLe study
S Quesada, A Puszkiel, A Jouinot, et al.
ESMO Open
|
April 16, 2025
Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial
M Saint-Ghislain, S Chabaud, F Dalenc, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 7, 2025
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer
A Mamann, Y Pradat, F C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 9, 2017
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab
J-Y Pierga, F-C Bidard, A Autret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2024
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
P Harter, C Marth, M-A Mouret-Reynier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 3, 2025
Dostarlimab and niraparib in primary advanced ovarian cancer
A-C Hardy-Bessard, E Pujade-Lauraine, R G Moore, et al.
Gynecologic Oncology
|
July 7, 2020
Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network
F Derquin, A Floquet, A C Hardy-Bessard, et al.
ESMO Open
|
May 1, 2024
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial
F Penault-Llorca, F Dalenc, S Chabaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 5, 2017
Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study
H Bourgeois, F Grudé, P Solal-Céligny, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
British Journal of Cancer
|
February 5, 2009
Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group
I Ray-Coquard, B Weber, J Cretin, et al.
ESMO Open
|
April 12, 2025
Exposure-response relationship of niraparib in maintenance therapy for recurrent ovarian cancer: ancillary analysis of the French GINECO-NiQoLe study
S Quesada, A Puszkiel, A Jouinot, et al.
ESMO Open
|
April 16, 2025
Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial
M Saint-Ghislain, S Chabaud, F Dalenc, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 7, 2025
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer
A Mamann, Y Pradat, F C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 9, 2017
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab
J-Y Pierga, F-C Bidard, A Autret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 11, 2024
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
P Harter, C Marth, M-A Mouret-Reynier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 3, 2025
Dostarlimab and niraparib in primary advanced ovarian cancer
A-C Hardy-Bessard, E Pujade-Lauraine, R G Moore, et al.
Gynecologic Oncology
|
July 7, 2020
Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network
F Derquin, A Floquet, A C Hardy-Bessard, et al.
ESMO Open
|
May 1, 2024
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial
F Penault-Llorca, F Dalenc, S Chabaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 5, 2017
Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study
H Bourgeois, F Grudé, P Solal-Céligny, et al.
Page
of 2